Introduction {#Sec1}
============

Polycystic Ovary Syndrome (PCOS) is a multifactorial pathology that affects 10% of the women in reproductive age being the main cause of infertility due to menstrual dysfunction\[[@CR1]--[@CR3]\]. Diagnosis is based on three different factors, identified during a consensus meeting sponsored by the European Society for Human Reproduction and Embryology (ESHRE) and the American Society for Reproductive Medicine (ASRM) held in Rotterdam in 2003: (1) oligo-anovulation, (2) hyperandrogenism (clinical or biochemical) and (3) the presence of 12 or more follicles in each ovary measuring 2--9 mm in diameter, and/or an increased ovarian volume (\>10 ml)\[[@CR2], [@CR3]\]. The identification of two out of three parameters allows to give the diagnosis of PCOS.

Since 1980, it is known that PCOS is associated with insulin resistance (IR). The recognition of this association has prompted extensive investigation on the relationship between insulin and gonadal function \[[@CR4]\]. Insulin acts synergistically with luteinizing hormone (LH) to enhance the androgen production of theca cells \[[@CR5]\]. Furthermore, it is able to reduce circulating levels of sex hormone binding globulin (SHBG), leading to increased levels of free testosterone \[[@CR6]\]. It has become clear that this syndrome has major metabolic as well as reproductive morbidities. Although the consensus meeting has decided to exclude IR from the diagnostic criteria, IR affects 50-80% of the patients with PCOS regardless BMI\[[@CR7]\]. Accordingly, this association has led to the treatment of PCOS women with insulin sensitizing agents such as troglitazone \[[@CR8]\], inositol \[[@CR9], [@CR10]\], metformin \[[@CR11]\] for restoring spontaneous ovulation.

In particular, several lines of evidence suggest that a deficiency of inositol, which is a second messenger of the insulin signaling, may be linked to insulin resistance\[[@CR12]\]. Inositol is a polyalcohol classified as insulin sensitizer and existing as nine stereoisomers, two of which are currently used in PCOS treatment: myo-inositol (MI) and D-*chiro*-inositol (DCI) \[[@CR9], [@CR13]\]. Both stereoisomers show an insulin-like action *in vivo* exerting the function of insulin mediators as inositolphosphoglycans (IPGs) \[[@CR14]\]. Indeed, MI is the most abundant form of inositol in humans while DCI is synthetized by an insulin-dependent epimerase that converts MI to DCI. Interestingly, every organ has a specific MI/DCI ratio likely linked to its specific needs (i.e. specific biological processes controlled be each inositol). Indeed, beside the common features, both inositols have specific action. DCI is able to induce glycogen synthesis; in particular, high DCI levels were identified only in glycogen storage tissues\[[@CR14]\]. On the other hand, MI plays a crucial role at ovarian level. Recently, Chiu et al. have reported that high concentrations of MI positively correlate with high quality and mature oocytes and a recent review clearly summarized the important role of MI in human reproduction \[[@CR15]\]\[[@CR16]\]. Furthermore, MI supplementation during IVF protocols has been shown to improve oocyte quality and reduce the number of IU of FSH necessary for ovarian stimulation \[[@CR17], [@CR18]\].

Oocyte quality is the main factor influencing the chance of a pregnancy; indeed, poor oocyte quality is a cause of infertility as well as an important obstacle for a successful *in vitro* fertilization (IVF).

Additional data have also shown that DCI supplementation at the dose of 1,2 g/die has no influence on ovarian response to exogenous FSH \[[@CR19]\]. The aim of the present study was to better investigate whether DCI has a role at ovarian level.

Materials and methods {#Sec2}
=====================

Patients {#Sec3}
--------

A total of 54 women, aged \<40 years and diagnosed with PCOS according to Rotterdam criteria, were enrolled in this study. All the subjects were selected among patients undergoing ICSI procedure that was suggested after evaluation of two different sperm samples of the male partner. ICSI patients were selected in order to minimize differences between semen samples. Patients with insulin resistance and/or hyperglycaemia were excluded from the study. In particular, insulin resistance was assessed by calculating the HOMA index, the cut-off defining insulin resistance was 3.2. Concomitantly hyperglycaemia was defied as glucose level \> than 140 mg/dl after 2h OGTT Patients were randomly divided into 5 groups (n = 10-12): a placebo group, and 4 groups (A-D) that received 300-600-1200-2400 mg of DCI (Interquim, s.a., Barcelona, Spain) daily respectively. All treatments were carried out for 8 weeks before follicle stimulating hormone (rFSH) administration. The randomization procedure was performed using a computer-based program. The Institutional Ethical Committee approved the protocol, and all patients gave a written informed consent before entering the study.

Controlled ovarian hyperstimulation {#Sec4}
-----------------------------------

All patients underwent pituitary desensitization by subcutaneous (s.c.) administration of the gonadotropin releasing hormone (GnRH) agonist (Decapeptyl; Ipsen, Paris, France) from midluteal phase until the day of intramuscular (i.m.) administration of 10,000 IU of human chorionic gonadotropin (hCG). Then, controlled ovarian hyperstimulation was performed in all patients by the administration of recombinant FSH (Gonal-F; Merck-Serono, Geneva, Switzerland). Starting dose was 150 IU per day. Patients were monitored by measuring the plasma concentration of 17β-Estradiol 2 (17β-E~2~) and the size of follicles on day 5 of the stimulation. The dosage of gonadotropin was adjusted according to the individual response. The 10,000 IU hCG was injected i.m. in all patients when serum 17β-E~2~ exceeded 200 pg per follicle and at least three follicles with a minimum diameter of 18 mm were found. Cycles were cancelled if E~2~ levels were \>4,000 pg/mL, due to increased risk of ovarian hyperstimulation syndrome (OHSS).

ICSI procedure {#Sec5}
--------------

According to Italian IVF law, a maximum of three oocytes per patient were injected, while spare mature oocytes were cryopreserved according to protocols described in previous studies \[[@CR20]\]. Oocyte and sperm preparation for conventional ICSI procedure have been thoroughly described elsewhere \[[@CR21]\]. Concerning ICSI, cumulus and corona radiata cells were immediately removed after retrieval by a short exposure to HEPES-buffered medium (Quinn's Advantage Hepes Medium; Sage IVF, Trumbull, CT, USA) containing 20 IU/mL hyaluronidase (Sage IVF) and by gentle aspiration in and out of a Pasteur pipette following by mechanical cleaning from the remaining surrounding cumulus cells by aspiration using a denuding pipette (Denuding Flexi-Pet; Cook, Brisbane, Australia) with a 170--130 mm diameter. The denuded oocytes were then assessed for their meiotic maturation status. In preparation for ICSI, oocytes with an extruded first polar body presumably at the metaphase II stage (MII) were selected (in a maximum of three) for the fresh cycle and spare MII oocytes were cryopreserved, if required \[[@CR22]\].

Luteal phase {#Sec6}
------------

Intramuscular administration of 50 mg daily progesterone in-oil was started on the day of ovum pick-up, and the treatment was performed daily until either a serum pregnancy test result was negative or an embryonic heart beat was sonographically confirmed.

Statistical analysis {#Sec7}
--------------------

Baseline characteristics and ovum pick-up outcomes were analyzed using One-way ANOVAs. The source of the detected significances was determined by Bonferroni post hoc test. *P* values less than 0.05 were considered statistically significant.

Results {#Sec8}
=======

Patients matching the inclusion criteria were randomized into five groups by a computer program. One-way ANOVA revealed no significant differences between groups in mean age, Body Mass Index at baseline (Table [1](#Tab1){ref-type="table"}). Total r-FSH units and number of days of stimulation differed between the groups. In particular, compared to the placebo group, the FSH IU administered were increased significantly in the two groups that received the higher doses of DCI (Table [2](#Tab2){ref-type="table"}). Estradiol levels at hCG administration were significantly different only in the group D (women treated with 1.2g of DCI Table [2](#Tab2){ref-type="table"}). The total number of oocytes retrieved were similar between the groups, while the number of immature oocytes (Figure [1](#Fig1){ref-type="fig"}, P \< 0.003) and number of MII oocytes (Figure [2](#Fig2){ref-type="fig"}, P = 0.0013) significantly differed. Indeed, the number of immature oocytes was significantly increased in the three groups that received the higher doses of DCI (P \< 0.04). Concurrently, the number of MII oocytes was significantly lower in the D group compared to placebo group (P \< 0.001). Noteworthy, the number of grade I embryos was significantly reduced by DCI supplementation (P = 0.004). Embryo quality was significantly reduced in women treated with 600, 1200 and 2400 mg of DCI (Figure [3](#Fig3){ref-type="fig"}).Table 1**Baseline characteristics of patients**PLACEBOA (DCI 300mg)B (DCI 600mg)C (DCI 1200mg)D (DCI 2400mg)***p***No. of patients1110111012NSAge (years)36.9 ± 1.536.8 ± 1.636.9 ± 1.5236.7 ± 1.5737.0 ± 1.25NSBMI (kg/m^2^)24.4 ± 2.825.2 ± 3.524.7 ± 3.525.1 ± 3.125.6 ± 2.9NSDuration of infertility (months)48.2 ± 9.449.4 ± 7.650.0 ± 7.249.9 ± 6.148.9 ± 8.8NSData are expressed as mean ± SD. Table 2**Clinical Data**PLACEBOA (DCI 300 mg)B (DCI 600mg)C (DCI 1200mg)D (DCI 2400mg)No. Oocytes retrieved8.99 ± 2.529.20 ± 2.469.13 ± 2.997.83 ± 2.787.23 ± 2.77Total rFSH (IU)2239.7 ± 181.552379.1 ± 353.802305.9 ± 150.192368.5 ± 235.77\*2983.0 ± 219.80\*\*17β-E2 levels (pg/ml)on hGC administration1429.69 ± 1118.431443.43 ± 1087.431350.06 ± 513.041530.85 ± 433.171490.24 ± 253.21 \*Stimulation (days)11.4 ± 1.212.1 ± 0.9912.5 ± 1.21 \*12.9 ± 1.10 \*\*13.8 ± 0.87\*\*No. Of cycles cancelled11002Data are expressed as mean ± SD.17β-E2 levels decreases in D group.\*, P \< 0.05 vs placebo. Stimulation days increase in B,C,D group (300, 600, 1200 mg DCI, respectively).\*, P \< 0.05 vs placebo, \*\*, P \< 0.01 vs placebo. Figure 1**Effects of DCI (300, 600, 2400 mg) on number of immature oocytes.** Data are expressed as mean ± SD. Number of immature oocytes increases after DCI administration. \*, P \<0.05 vs. placebo;\*\*, P \<0.001 vs. placebo (n = 10-11 per group) Figure 2**Effects of DCI (300, 600, 2400 mg) on number of MII oocytes.** Data are expressed as mean ± SD. Number of MII occytes decreases after DCI administration. \*\*P \<0.01 vs.placebo, \*\*\*, P \<0.001 vs.placebo (n = 10-11 per group) Figure 3**Effects of DCI (300, 600, 2400 mg) on number of embryo grade I.** Data are expressed as mean ± SD. Number of embryo grade I decreases after DCI administration. \*\*, P \<0.01 vs. placebo, \*\*\*, P \<0.001 vs. placebo (n = 10-11 per group)

Discussion {#Sec9}
==========

In the present study we were able to show that DCI negatively affects oocyte quality. Indeed, increasing DCI dosage progressively worsens oocyte quality and ovarian response in non-obese and non insulin resistant PCOS women. Literature data clearly show that the two inositol stereoisomers have different physiological roles: while DCI is crucial for glycogen synthesis, MI increases glucose cellular uptake \[[@CR12]\]. Interestingly, each tissue has its own MI/DCI ratio and the relative amount of each inositol in a certain tissue reflects inositol(s) specific functions. Indeed, high DCI levels (always lower than MI) are present only in glycogen storage tissues (fat, liver and muscle), while very low levels of DCI are characteristic of tissues that have high glucose utilization, likely because they need to "have a high energy status" (brain and heart) \[[@CR14]\]. Recently a new manuscript pointed out that one of the causes of poor oocyte quality in PCOS women might be the reduced energy metabolism \[[@CR23]\]. Indeed, literature data have shown that in PCOS women, genes involved in the glucose uptake pathway are downregulated at ovarian level \[[@CR24]\]. These data are indeed in line with the findings of Carlomagno et al., that in a comparative study (MI vs. DCI) highlighted that only MI has an action at ovarian level; since MI is responsible of glucose cell uptake, likely it improves ovary energy status and therefore, it is able to improve oocyte quality \[[@CR19], [@CR23]\]. *In vivo*, DCI is synthetized by an epimerase that converts MI into DCI and, depending on the specific needs of the two different molecules, each tissue has a typical conversion rate. In particular, it has been shown that the ratio of these two insulin mediators is insulin dependent\[[@CR25], [@CR26]\]. Indeed, in subjects with type 2 diabetes, the DCI/MI ratio is reduced and less DCI is synthetized, due to a reduction in the epimerase activity \[[@CR25], [@CR26]\]. Unlike other tissues such as muscle and liver, ovary never become insulin resistant \[[@CR27], [@CR28]\]. Therefore, it can be speculated that PCOS patients with hyperinsulinemia probably present an enhanced MI to DCI epimerization rate in the ovary that would result in an increased DCI/MI ratio (i.e., overproduction of DCI), and in a MI deficiency. This MI depletion could eventually be responsible for the poor oocyte quality observed in these patients \[[@CR29]\]. In addition, the positive effects of MI supplementation \[[@CR17]--[@CR19], [@CR30]\] might be explained by the fact that restoring MI levels will improve ovarian response to FSH; furthermore, since MI is responsible for glucose cell intake, energy status will be restored as well. Nestler et al. in 1999 showed for the first time that administration of DCI (1.2 g/d) in obese PCOS women is able to restore ovulation after 4 weeks of treatment, although no data on menstrual regularity were reported\[[@CR9]\]. However, in a second study conducted by the same authors, DCI dosage was doubled (2400 mg/die) and authors were not able to confirm their pervious findings.\[[@CR31]\] Our results seems to be in line with the DCI paradox hypothesis \[[@CR29]\]. Indeed, increasing DCI dosage progressively negatively influences oocyte and embryo quality. Similar results have been obtained by treating PCOS woman scheduled for IVF with metformin, 500 mg three times per day\[[@CR32]\]. Metformin decreased the number of dominant follicles, retrieved oocytes, and MII oocytes, despite increased IU of gonadotropin were administered. Baillargoen et al. showed that metformin increased the insulin-stimulated release of DCI-phosphoglycans; therefore, we could hypothesize that metformin promotes glycogen synthesis and further reduces ovary energy status through DCI phosphoglycans \[[@CR33]\]. Based on this evidence, we can speculate on the reason why Nesteler had opposite results in the two trials. In the first study, DCI supplementation restored ovulation probably due to a peripheral action of DCI, allowing to restore epimerase physiological rating into the ovary. In the second trial, the lack of positive effects after 2400mg DCI supplementation was probably due to an overload of DCI (pre-existent high levels of DCI in the ovary and supplementation). In conclusion, we have shown that DCI supplementation reduces oocyte quality; therefore the administration of DCI cannot be considered as an appropriate approach to improve IVF outcomes in PCOS patients.
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